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SARS-CoV-2-mediated dysregulation of
metabolism and autophagy uncovers
host-targeting antivirals
Viruses manipulate cellular metabolism and macromolecule recycling processes like autop-
hagy. Dysregulated metabolism might lead to excessive inflammatory and autoimmune
responses as observed in severe and long COVID-19 patients. Here we show that SARS-CoV-2
modulates cellular metabolism and reduces autophagy. Accordingly, compound-driven
induction of autophagy limits SARS-CoV-2 propagation. In detail, SARS-CoV-2-infected cells
show accumulation of key metabolites, activation of autophagy inhibitors (AKT1, SKP2) and
reduction of proteins responsible for autophagy initiation (AMPK, TSC2, ULK1), membrane
nucleation, and phagophore formation (BECN1, VPS34, ATG14), as well as autophagosome-
lysosome fusion (BECN1, ATG14 oligomers). Consequently, phagophore-incorporated autop-
hagy markers LC3B-II and P62 accumulate, which we confirm in a hamster model and lung
samples of COVID-19 patients. Single-nucleus and single-cell sequencing of patient-
derived lung and mucosal samples show differential transcriptional regulation of autophagy and
immune genes depending on cell type, disease duration, and SARS-CoV-2 replication levels.
Targeting of autophagic pathways by exogenous administration of the polyamines spermidine
and spermine, the selective AKT1 inhibitor MK-2206, and the BECN1-stabilizing anthelmintic
drug niclosamide inhibit SARS-CoV-2 propagation in vitro with IC50 values of 136.7, 7.67, 0.11,
and 0.13 μM, respectively. Autophagy-inducing compounds reduce SARS-CoV-2 propagation in
primary human lung cells and intestinal organoids emphasizing their potential as treatment
options against COVID-19.
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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses an imminent threat to global health. As of 18May 2021, >162,000,000 individuals were infected in >220
countries, with >3,375,000 fatalities1. SARS-CoV-2 infections
cause CoV infectious disease 19 (COVID-19) in humans, which is
associated with common cold symptoms (dry cough, fever, fati-
gue, shortness of breath, sore throat), but also with olfactory and
taste disorders, dyspnoea, and severe pneumonia2.
Compound-based targeting of cellular proteins that are essential
for the virus life cycle has led to the discovery of broadly reactive
drugs against a range of CoV3. However, undirected approaches
often provide limited insight into the molecular and functional
details on how the drugs affect virus propagation4,5. As virus
propagation depends on energy and metabolic substrates of host
cells, drug target identification should consider the metabolism of
infected cells3. Dysregulations and age-dependent decline of mul-
tiple metabolic processes in humans are associated with comor-
bidities like diabetes, hypertension, and obesity, which are believed
to influence COVID-19 severity6. Catabolic recycling processes
such as the ubiquitin-proteasome system (UPS) and macro-
autophagy (hereafter referred to as autophagy) maintain energy
and protein homeostasis in cells7. The UPS facilitates ubiquitin-
targeted rapid degradation of proteins via the proteasome8.
Autophagy, which is tightly controlled by metabolism, is a highly
conserved lysosomal degradation process of long-lived proteins,
lipids, and organelles in eukaryotic cells9,10. The mechanistic target
of rapamycin complex 1 (mTORC1) and AMP-activated protein
kinase (AMPK) regulate autophagy by responding to metabolic
alterations via continuous crosstalk with glucose and protein
homeostasis11. mTORC1 activity is, for example, increased in
response to high intracellular amino acid levels, stimulates anabolic
cell growth, and inhibits autophagy to reduce untargeted protein
degradation12. Increased AMP and low glucose levels trigger
AMPK, indicating energy and amino acid deficiency, and resulting
in autophagy activation13. Mitochondrial turnover (mitophagy)
and reactive oxygen species (ROS)-dependent polyamine pathways
also promote autophagy14,15. Polyamines are generated as part of a
gradual amino acid degradation process turning arginine to orni-
thine and subsequently via putrescine to spermine and spermidine.
Both, spermine and spermidine, can be converted to putrescine via
their acetylated forms (NAcspm, NAcspd) by spermidine-spermine
acetyltransferase (SAT1), promoting cellular export of polyamines,
and restricting replication of several RNA viruses16–18. Spermidine
hypusinates eukaryotic translation initiation factor eIF5A15, which
functions globally in translation elongation and termination and
activates lysosomal biogenesis as well as autophagy transcription
factor EB (TFEB). TFEB is a key regulator for proteins responsible
for autophagy and mitochondrial respiration15,19.
During autophagy, intracellular macromolecules are recycled by
incorporation into microtubule-associated proteins 1 A/1B light
chain 3B (LC3B)-lipidated autophagosomes (AP) and degradation
into their monomers, such as fatty and amino acids, after fusion
with acidic lysosomes20. In the case of highly pathogenic Middle
East respiratory syndrome (MERS)-CoV, we recently showed that
autophagy is limited by a virus-induced AKT1-dependent acti-
vation of S-phase kinase-associated protein 2 (SKP2), an E3-ligase,
which targets the key autophagy-initiating protein Beclin-1
(BECN1) for proteasomal degradation21. BECN1 degradation
led to reduced ATG14-dependent fusion of AP with lysosomes22
and resulted in accumulated AP, lipidated LC3B (LC3B-II), and
P62 levels through blockage of autophagic flux. We assumed that
MERS-CoV-induced reduction of autophagy might prevent
degradation of virus proteins and enhance CoV-driven exploita-
tion of lipid resources required for the production of infectious
virus particles23,24. Finally, inhibition of SKP2 by different com-
pounds, including clinically approved drugs, stabilized BECN1
and limited MERS-CoV propagation21, indicating that autophagy-
inducing compounds hold promise as antiviral drugs.
However, detailed mechanisms on how highly pathogenic CoV
accomplish metabolic reprogramming and secure lipid and amino
acid availability without activating antiviral counteractions are
largely unknown. In this interdisciplinary and translational study
we investigate the impact of SARS-CoV-2 infection on cell
metabolism and the downstream effects on catabolic autophagy
in vitro, ex vivo, and in vivo, thereby identifying multiple targets
for the application of approved drugs and the development of
antiviral therapies.
Results
SARS-CoV-2 causes accumulation of key metabolites in
infected cells. To explore the putative impact of SARS-CoV-2
infection on central carbon metabolism, we performed a targeted
metabolomic analysis on SARS-CoV-2-susceptible, interferon
(IFN)-deficient, VeroFM monkey kidney cells and IFN-competent
human lung Calu-3 cells5. The initial metabolite profiles were
analyzed by multivariate principal component analysis (PCA), an
unsupervised statistical method suitable for analyzing and classi-
fying metabolomics datasets25. The profiles separated SARS-CoV-2
and control group (CoV-2 vs mock; Supplementary Fig. 1 (amine-
containing) and Supplementary Fig. 2 (anion-containing)). In
detail, 37/90 (VeroFM) and 55/93 (Calu-3) analyzed metabolites
were significantly altered (cutoff: FDR-corrected p < 0.05, normal-
ized to cell counts) upon SARS-CoV-2 infection (Supplementary
Tables 1 (VeroFM), 2 (Calu-3); and Supplementary Fig. 3).
Whereas in the VeroFM cells all differential metabolites were
significantly increased upon SARS-CoV-2 infection, the Calu-3
cells showed 47 metabolites that were significantly increased, while
8 metabolites were significantly decreased (Supplementary Fig. 3,
Supplementary Tables 1–2). The differentially regulated metabo-
lites comprised 15 metabolic pathways (Fig. 1a, VeroFM; Fig. 1b,
Calu-3). Major changes were linked to amino acid pool sizes,
comprising phenylalanine (phe), tyrosine (tyr), glycine (gly), serine
(ser), and threonine (thr) metabolism, but also to metabolites of
glyoxylate, dicarboxylate, pantothenate, and pyrimidine metabo-
lism. High systemic amino acid levels (Fig. 1c, orange) might be
explained by different mechanisms including SARS-CoV-2 NSP1-
mediated translational shutdown26,27, modulated catabolic pro-
cesses, or increased amino acid biosynthesis. To explore if high
amino acid levels result from de novo biosynthesis, we performed
U-13C6 glucose isotope enrichment analysis in SARS-CoV-2- and
mock-infected Calu-3 cells (Supplementary Fig. 4a, b; Supple-
mentary Tables 3–4). As relative 13C enrichment of the most
abundant amino acids and intermediates of glycolysis and the TCA
cycle (Supplementary Fig. 4a, b) showed minor differences between
the SARS-CoV-2- and mock-infected cells, we focused our analyses
on catabolic protein degradation via the UPS or autophagy.
SARS-CoV-2-induced catabolic UPS, as shown by a global increase
of K48-ubiquitinated proteins (Supplementary Fig. 5a), likely
increases the availability of proteasome-derived amino acids
necessary for virus production28. Congruently, inhibition of pro-
teasomal degradation by MG132 reduced infectious virus particle
production (Supplementary Fig. 5b). As shown for MERS-CoV,
limited autophagy might additionally reduce the overall rate of host
protein degradation which is supported by the high levels of amino
acids and nucleoside triphosphates (Fig. 1c, orange and blue; ATP,
GTP, CTP, UTP). Furthermore, high levels of putrescine (Fig. 1c,
red) hint towards increased SAT1 activity, which is a known
autophagy inducer15. Re-analyzed bulk and single-cell RNA-
sequencing datasets of Calu-3 cells29 show increased SAT1
expression in SARS-CoV-2-infected cells (Supplementary Fig. 5c).
SAT1 is a known IFN-stimulated gene18 and its upregulation was
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comparable to other prototypic innate immune genes (IFIT1,MX1,
MX2; Supplementary Fig. 5d) in SARS-CoV-2-infected cells, which
confirms the proposed connection between the innate immune
response and the polyamine metabolism. A SAT1-induced shift of
spermidine to putrescine might limit hypusination of eIF5A and
downstream activation of autophagy genes15. Indeed, tran-
scriptome analysis showed that the majority (n= 399) of the
471 TFEB-regulated autophagy target genes from the CLEAR
network30 were downregulated in SARS-CoV-2-infected Calu-3
cells (Supplementary Fig. 5e). Interestingly, MAP1LC3B and
SQSTM1 encoding key autophagy markers LC3B and P62
remained unaffected whereas CD63 and RAB7A, which are both
associated with vesicular and membrane trafficking30 were down-
regulated (Supplementary Fig. 5f).
SARS-CoV-2 limits autophagy signaling and blocks autophagic
flux. In our metabolomics dataset we identified key metabolites,
which regulate the activity of autophagy-modulating AMPK
(AMP/ATP ratio) and mTORC1 (amino acids). Next, we aimed to
investigate SARS-CoV-2-specific effects on autophagy-linked
proteins by applying previously established assays21 according to
the expert-curated guidelines for monitoring autophagy31. We,
Fig. 1 SARS-CoV-2 causes accumulation of key metabolites in infected cells. a, b Analysis and regulation of significantly altered pathways of mock- and
SARS-CoV-2-infected (24 h p.i., MOI= 0.1) VeroFM cells (a) or Calu-3 cells (b). The y-axis shows the (median) log2 fold change (FC) of all significantly
altered metabolites of the indicated pathway while the –log10 corrected p-value (false discovery rate (FDR)) is shown on the x-axis. The size of the circles
illustrates the number of significantly changed metabolites in relation to all metabolites of a specific pathway. c Analysis of the autophagic pathway and the
involved metabolites: ‘amino acids’ and ‘GSH metabolism’ (orange), ‘nucleotides’ (blue), ‘glycolysis’ (green), ‘polyamine metabolism’ (red) and ‘O-
GalNAcylation’ (purple) in mock- and SARS-CoV-2-infected (24 h p.i.) VeroFM and Calu-3 cells. For a–c Error bars represent SEM. n= 4 biological
samples per group of one experiment. All p-values were determined by a two-way ANOVA and Tukey´s post hoc test. FDRs were adjusted using the
Benjamini-Hochberg method. Abbreviations: 1,3-BPG, 1,3-bisphosphoglyceric acid; 3-PGA, 3-phosphoglyceric acid; ADP, adenosine diphosphate; AKT1,
RAC-alpha serine/threonine-protein kinase; ala, alanine; AMP, adenosine monophosphate; AMPK, AMP-activated protein kinase; arg, arginine; asn,
asparagine; asp, asparagine; ATP, adenosine triphosphate; aut, autophagosome; BECN1, beclin-1; bio., biosynthesis; CTP, cytidine triphosphate; CoA,
coenzyme A; cys, cysteine; cysgly, cysteinylglycine; cyst, cystathionine; dCTP, deoxycytidine triphosphate; dicarbox., dicarboxylate; elF5AH, eukaryotic
translation initiation factor 5A hypusinated; EP300, histone acetyltransferase p300; F1P, fructose 1-phosphate; F6P, fructose 6-phosphate; F-1,6-BP,
fructose 1,6-bisphosphate; FKBP51, 51 kDa FK506-binding protein; G6-P, glucose 6-phosphate; gln, glutamine; glu, glutamic acid; gly, glycine; glyox,
glyoxylate; GSH, glutathione (reduced); GTP, guanosine triphosphate; hcys, homocysteine; his, histidine; ile, isoleucine; lac, lactic acid; leu, leucine; lys,
lysine; mal, malic acid; met, methionine; met., metabolism; modific., modification; mTORC1, mechanistic target of rapamycin complex 1; NAcput, N-
acetylputrescine; NAcspd, N-acetylspermidine; orn, ornithine; PEP, phosphoenolpyruvic acid; phe, phenylalanine; PHLPP, PH domain leucine-rich repeat-
containing protein phosphatase; PPP, pentose phosphate pathway; pro, proline; prot., protein; put, putrescine; pyr, pyruvic acid; resid., residue; ROS,
reactive oxygen species; S7P, sedoheptulose-7-phosphate; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; SAT1, diamine acetyltransferase 1;
SKP2, S-phase kinase-associated protein 2; ser, serine; spd, spermidine; spm, spermine; tau, taurine; TFEB, transcription factor EB; thr, threonine; trp,
tryptophan; tyr, tyrosine; UDP-GalNAc, UDP-N-acetylgalactosamine; UDP, uridine diphosphate; UTP, uridine triphosphate; val, valine.
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therefore, monitored protein expression levels by Western blot
analyses after infection of VeroFM cells with SARS-CoV-2 or
heat-inactivated virus as control (Fig. 2a). Based on our previous
experience with MERS-CoV21, we chose a low MOI of 0.0005 and
time points 8, 24, and 48 h post infection (h p.i.) to dissect
autophagy during the exponential growth of SARS-CoV-2 (Sup-
plementary Fig. 6a). SARS-CoV-2 infection influenced most of the
analyzed components of the AMPK/mTORC1 pathway (Fig. 2a).
Phosphorylated, active forms of AMPK (pAMPKT172), AMPK
substrates (LXRXX(pS/pT)), and AMPK downstream targets
(pTSC2S1387 and pULK1S556) were reduced upon SARS-CoV-2
infection, suggesting that a high ATP/AMP ratio is maintained
via a virus-induced decrease of host protein translation. The
metabolomics data (see Fig. 1) also revealed cellular amino acid
sufficiency, consistent with high levels of mTORC1 activity.
Indeed, mTORC1-dependent phosphorylation of ULK1 at S757
was maintained around the basal level throughout the course of
infection (Fig. 2a, ULK1S757), suggesting that SARS-CoV-2 avoids
triggering starvation-induced autophagy. In addition, we found
increased levels of pAKT1S473, which may be explained by SARS-
CoV-2-induced growth factor signaling in line with previously
described elevated class I phosphatidylinositol 3-kinase (PI3K)
activity and AKT1 phosphorylation32. AKT1 activates the
BECN1-targeting E3-ligase SKP2 through phosphorylation at
S7221. Congruently, CDK2-dependent and SKP2-activating
phosphorylation of SKP2 at position S6433 was enhanced
(Fig. 2a, pSKP2S64). Consequently, we found low BECN1 levels
and reduced ULK1-dependent pBECN1S15, which is in agreement
with subsequently reduced ATG14 phosphorylation (pATG14S29)
and ATG14 homo-oligomerization (Fig. 2a). BECN1 is a key
factor of the phagophore-nucleation complex consisting of VPS34,
ATG14, AMBRA1, and p11534. In line with BECN1 reduction, we
also detected reduced GFP-FYVE signals, an established reporter
for VPS34 (class III PI3K) activity35, in SARS-CoV-2-infected
VeroFM cells (Supplementary Fig. 6b). The above-mentioned
reduction of ATG14 oligomers, known to facilitate fusion via
SNARE proteins SNAP29 and STX1721, and promoting fusion of
APs with lysosomes22, indicated a disruption of vesicular fusion
and reduction of autophagic flux. By using a well-established
autophagy reporter assay, we assessed autophagosome-lysosome
(AL) fusion, a hallmark of autophagic flux36. The number of low-
pH ALs (in red) in mRFP and pH-sensitive EGFP dual-tagged
LC3B-expressing and SARS-CoV-2-infected VeroFM (Fig. 2b,
Supplementary Fig. 6c) and human bronchiolar NCI-H1299 cells
(Supplementary Fig. 6d) was reduced compared to mock-infected
cells indicating a virus-induced reduction of AL fusion. In
VeroFM cells, the total number of ALs was reduced from a mean
of 58 to 39 vesicles per cell, whereas the number of APs per
cell was comparable (mock= 25 vesicles/cell; SARS-CoV-2= 27
vesicles/cell). The ratio of APs to ALs shifted in SARS-CoV-2-
infected cells, indicating relative AP accumulation compared to
AL (mock= 0.431 ± 0.050; SARS-CoV-2= 0.674 ± 0.076) (Fig. 2b,
Supplementary Fig. 6c-d). The reduction of autophagic flux was
confirmed by elevated levels of the autophagy receptor P62 in
SARS-CoV-2-infected cells (Fig. 2c; Supplementary Figure 7a,
NCI-H1299). As transcriptional regulation of P62-mRNA was
minor in SARS-CoV-2-infected VeroFM cells at 8 and 24 h p.i.
and max. 3-fold at 48 h p.i. (Supplementary Fig. 7b), the lack of
AL fusion was most likely responsible for increased P62 protein
levels. For further confirmation and to assess the effect of the
proposed SARS-CoV-2-induced block of the autophagic flux, we
co-treated SARS-CoV-2-infected VeroFM and NCI-H1299 cells
with optimized amounts of bafilomycin A1 (BafA1, 100 nM,
Supplementary Fig. 7c) and determined LC3B-II levels as a marker
for phagophore/AP accumulation (Fig. 2d, VeroFM and Supple-
mentary Fig. 7d, NCI-H1299). BafA1 is an inhibitor of vacuolar
H+-ATPase (vATPase), an enzyme essential for lysosome acid-
ification and degradation of AP cargo. BafA1 treatment prevents
the formation of autophagy-active ALs from AL fusion31.
Immunoblot analysis of LC3B-II in the presence of 100 nM BafA1
indicated that mock-infected cells showed a significant increase of
the LC3B-II/actin ratio due to the BafA1-induced inhibition of
autophagic flux, whereas SARS-CoV-2 infection alone was suffi-
cient to elevate the LC3B-II/actin ratio (Fig. 2d, Supplementary
Fig. 7d, NCI-H1299). At 8 h p.i., LC3B-II levels were slightly
elevated in SARS-CoV-2-infected cells, but could still be enhanced
by BafA1 treatment. At 24 and 48 h p.i., vehicle- or BafA1-treated
and SARS-CoV-2-infected cells showed equally limited autophagic
flux (Fig. 2d). In sum, SARS-CoV-2 infection activated negative
regulators of autophagy, reduced autophagy-enhancing proteins,
and limited autophagic flux by diminishing BECN1/ATG14-
dependent AL fusion.
SARS-CoV-2 replication-dependent and cell-specific regulation
of autophagy in vivo. To explore if SARS-CoV-2 reduces autop-
hagic flux in vivo, we analyzed lung samples from SARS-CoV-2-
infected Syrian hamsters37. Protein samples were taken at 2, 3, 5,
and 14 days post infection. As described previously, virus propa-
gation in the lung reached the highest titers at days 2 and 3 (108
PFU/g) with subsequent reduction to 105 PFU/g at day 5 followed
by viral clearance at days 7 and 1437. Particularly in aged hamsters,
we found highly increased P62 and LC3B-II protein levels at day 3
(Fig. 3a). At the same time, mRNA levels of Map1lc3b and Sqstm1
remained overall unchanged throughout the course of infection
(Supplementary Fig. 8) suggesting that increased P62 and LC3B-II
levels were not caused by transcriptional upregulation, but rather
accumulated by a SARS-CoV-2-induced blockage of autophagy.
Furthermore, we compared postmortem lung samples of COVID-
19 patients (n= 6) with lung sections of other pneumonia patients
(n= 3) or deceased due to other causes (n= 3) by immunohisto-
chemical staining of P62 and LC3B (Supplementary Tables 5, 6).
More LC3B- and particularly P62-positive cells were identified
in COVID-19 patient lung samples, which might be explained
by increased MAP1LC3B and SQSTM1 mRNA levels or again by a
reduced autophagic flux and protein accumulation (Fig. 3b, Sup-
plementary Table 6). To distinguish between these possible expla-
nations, we performed sNuc-seq-based transcriptional analyses for
seven deceased individuals with severe COVID-19, of which three
deceased early (<14 days) and four late (>14 days) post onset of
symptoms (Supplementary Table 7). Cell types were defined as
previously described38 (Supplementary Fig. 9a–i). The analyses
focused on autophagy-affected genes (SQSTM1, MAP1LC3B,
CD63, RAB7A), ROS-induced NQO1 to monitor NRF-2
activation, autophagy-affecting polyamine-regulating SAT1 and
IFN-stimulated genes (ISGs) MX1, IFIT1, ISG15 and IFITM3 in
multiple cell types (Supplementary Fig. 9j) especially secretory,
ciliated and AT2 cells, as the latter two are the predominant target
cells for SARS-CoV-2 infection39 (Fig. 3c). In secretory cells (Fig. 3c,
left), most target genes were comparably expressed between control
and early-deceased COVID-19 patients but downregulated in cells
from late-deceased individuals. In the main SARS-CoV-2 target
cells (ciliated, AT2), we observed a similar pattern between early-
and late-deceased patients. However, mRNA levels for IFN-
stimulated and autophagy genes were much more increased com-
pared to secretory cells and were highly comparable to a cellular
subpopulation in which high viral RNA levels were detected
(Fig. 3c, SARS2high, Supplementary Fig. 9d). SAT1 mRNA levels
were similar to those of all other ISGs, further supporting a link
between IFN response and polyamine-dependent autophagy inter-
ventions (see Fig. 1c). As early- compared to late-deceased patients
showed higher virus RNA levels (>105 virus RNA copies per 10,000
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Fig. 2 SARS-CoV-2 limits autophagy signaling and blocks autophagic flux. a Protein levels and phosphorylation status of selected autophagy-relevant
proteins in SARS-CoV-2-infected VeroFM cells at 8 h, 24 h, or 48 h post infection (h p.i.) were analyzed by Western blotting. For analysis of ATG14
oligomers (virtual blot, bottom panel, left) proteins were cross-linked 2 h prior to cell harvest and analyzed by Wes (ProteinSimple) capillary electrophoresis
8-48 h p.i. P-values were determined by one-way ANOVA, Bonferroni post hoc test. b Fluorescence microscopy of transfected and SARS-CoV-2-infected
VeroFM cells expressing pH-sensitive tandem fluorescent-tagged LC3B-mRFP/EGFP showed that low pH autophagolysosomes (AL, red) were reduced
compared to autophagosomes (AP, green + red = yellow) in virus-infected cells. Microscopic read-out was done by a scientist blind to the experimental
conditions. For mock (n= 44 cells) and SARS-CoV-2-infected (n= 46 cells) VeroFM cells were analyzed. P-values were determined by two-way ANOVA,
Tukey´s post hoc test, mean with SEM. Scale bar = 10 µM. c Accumulation of autophagy marker P62 in SARS-CoV-2-infected VeroFM cells. d Elevated
LC3B-II levels in SARS-CoV-2-infected and bafilomycin A1 (BafA1)-pretreated VeroFM cells indicate virus-induced autophagic flux inhibition at 8 and 24 h
p.i. In all panels, error bars denote SEM derived from n= 3 biologically independent samples derived from one experiment. P-values were determined by
two-way ANOVA, Sidak post hoc test. p≤ 0.05 (*), p≤ 0.01 (**), p≤ 0.001 (***), p≤ 0.0001 (****), p > 0.05 (not significant, ns). Abbreviations: AKT1,
RAC-alpha serine/threonine-protein kinase; AMPK, AMP-activated protein kinase; ATG14, autophagy-related 14; ATG16L1, autophagy-related 16 like 1;
BafA1, bafilomycin A1; BECN1, Beclin-1 protein; CDK2, cyclin-dependent kinase 2; EGFP, enhanced green fluorescent protein; LC3B, microtubule-associated
protein 1 A/1B light chain 3B; LXRXX(pS/pT), phospho-AMPK substrate motif; mRFP, monomeric red fluorescent protein; mTORC1/2, mechanistic target of
rapamycin complex 1/2; PRAS40, proline-rich AKT1 substrate 1; Rheb, Ras homolog enriched in brain; SKP2, S-phase kinase-associated protein 2; TSC1/2,
tuberous sclerosis 1/2; ULK1, Unc-51-like kinase 1; VPS34, phosphatidylinositol 3-kinase catalytic subunit type 3.
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cells, Supplementary Table 7), we suspected that SARS-CoV-2
replication levels might influence transcriptional regulation. To
further explore this, we re-analyzed single-cell sequencing (scSeq)
data sets from mucosal brushes of hospitalized COVID-19
patients38 experiencing low to moderate (<105 GE/ml, n= 5) or
high (>105 GE/ml, n= 3) virus RNA concentrations (Supplemen-
tary Table 8). Seven out of 8 patients were severely ill and all
samples were taken within the main phase of virus replication (first
11 days post onset of symptoms)40. In patients with low SARS-
CoV-2 RNA levels, we found that prototypic autophagy-related
Fig. 3 SARS-CoV-2 replication-dependent and cell-specific regulation of autophagy in vivo. a Enhanced relative LC3B-II/HSC70 and P62 protein levels in
lung samples of SARS-CoV-2-infected compared to mock-infected hamsters (dotted line). Syrian hamsters (Mesocricetus auratus, n= 3 per group, one
experiment) were infected or mock-infected (heat-inactivated virus) with 1x10e5 plaque-forming units SARS-CoV-2 by intranasal instillation. Lung samples
were taken at days 2, 3, 5, 14 post infection, and protein lysates were analyzed by Western blotting. P-values were determined by two-way ANOVA, Tukey
´s post hoc test, mean with SD. b Immunohistochemistry (IHC). Increased amount of P62 and LC3B-positive cells in formalin-fixed and antibody-stained
lung samples from deceased COVID-19 (n= 6), pneumonia (n= 3), and control patients (n= 3). For each sample, 4 randomly chosen microscopic fields
(40x) were independently rated by two persons. P-values were determined by one-way ANOVA, Dunnett´s, mean with SEM. Scale bar = 100 µM. c Dot
plots depicting scaled average expression of autophagy and immune genes for selected cell types from postmortem lung patient samples separated
according to disease duration representing patients deceased within 14 days (early, n= 3) and after 14 days (late, n= 4). d Expression profile of distinct
cell types from the olfactory mucosa of COVID-19 patients (n= 8) separated according to viral loads and compared to healthy controls (n= 5). Cut-off for
the categories “low” (n= 5) and “high” (n= 3) was 10e5 GE per ml swab-derived liquid. Scaled expression levels are color-coded and the percentage of
cells expressing the gene is size-coded. Differential expression analyses were calculated with MAST, and p-values were adjusted with the Benjamini-
Hochberg method. For comparisons to the uninfected control, significance is indicated by a black circle. For comparisons between conditions (early vs. late
or low viral load vs. high viral load) significance is depicted by an asterisk. p≤ 0.05 (*), p≤ 0.01 (**), p≤ 0.001 (***), p≤ 0.0001 (****), p > 0.05 (not
significant, ns). Ave. Exp. = average expression, Pct. Exp. = percent of cells expressing the gene.
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transcription of SQSTM1, MAP1LC3B, CD63, and RAB7A was
upregulated in secretory cells and comparable or even reduced in
putatively SARS-CoV-2-infected ciliated cells (Fig. 3d). Con-
gruently, and similar to our in vitro metabolomics data (see Fig. 1),
polyamine-regulating SAT1 was significantly increased in ciliated
cells of patients with low SARS-CoV-2 RNA concentrations
(Fig. 3d), possibly facilitating downregulation of TFEB-regulated
genes like CD63. Interestingly, in ciliated cells of patients with high
SARS-CoV-2 RNA levels, ISGs were upregulated, whereas SAT1
showed low expression levels and autophagy genes were compar-
ably expressed or moderately upregulated, the latter being equiva-
lent to early-deceased COVID-19 patients (see Fig. 3c). The
differences in transcriptional regulations between secretory and
ciliated, early- and late-deceased, as well as low and high SARS-
CoV-2 RNA concentrations, imply that autophagy gene regulation
is differentially controlled, depending on cell type, disease duration,
and SARS-CoV-2 replication levels.
Autophagy induction limits SARS-CoV-2 growth. As SARS-
CoV-2 modulated several metabolic pathways (see Fig. 1) and
limited autophagy in vitro and in vivo (see Figs. 2 and 3), we
targeted key components of the catabolic/autophagy signaling by
exogenous administration of selective inhibitors, approved drugs,
or cellular metabolites and explored the effect on SARS-CoV-2
propagation (Fig. 4). To exclude toxicity of the applied com-
pounds, multiple cell viability tests (MTT, LDH, and PrestoBlue)
were performed (Supplementary Fig. 10). VeroFM cells were
infected and treated with different concentrations of each com-
pound according to previous publications and cytotoxicity profile
(Supplementary Fig. 10; Supplementary Table 9). Virus growth
was monitored by plaque assays to quantify the infectious par-
ticles and real-time RT-PCR to detect genome equivalents per ml
(GE/ml) in cell culture supernatants 24 and 48 h p.i. (Supple-
mentary Fig. 11a). For key autophagy proteins, siRNA-based
knockdown experiments were additionally performed (Fig. 4,
green columns, Supplementary Fig. 11b). The effects of all sub-
stances were monitored during the exponential growth phase of
the virus at 24 h p.i. to circumvent interfering effects like cyto-
pathogenicity and apoptosis (Fig. 4).
Elevated putrescine and N-acetylputrescine levels suggested that
SARS-CoV-2 reduces autophagy-inducing polyamine levels (see
Fig. 1). Indeed, exogenously applied spermidine and spermine
(both 100 µM) inhibited production of infectious SARS-CoV-2
particles by 87% and 54% or GE/ml by 65% and 80%, respectively
(Fig. 4, top row, Supplementary Fig. 11a) without causing bovine
serum- or ROS-induced cytotoxicity41 (Supplementary Figs. 10 and
11c). AICAR (25 µM), an AMP analog known to induce autophagy
via AMPK activation42 and inhibit autophagy through promotion
of BECN1-VPS34 dissociation43 had no effect on infectious particle
production, but slightly enhanced GE production (Fig. 4, top,
Supplementary Fig. 11a). mTORC1 inhibition by rapamycin
(0.3 µM), known to induce autophagy, slightly reduced PFU/ml
at 24 h p.i. (29%), but increased GE/ml by 101% (Fig. 4, top,
Fig. 4 Autophagy induction limits SARS-CoV-2 growth in vitro. Schematic
representation of autophagy signaling indicating site of action of small-
molecule compounds (orange columns) or siRNA knockdown (green
columns) used for pathway modulation. VeroFM cells were infected with
SARS-CoV-2 (MOI= 0.0005) and treated with the indicated compounds:
polyamines spermidine (spd, 100 µM) and spermine (spm, 100 µM), AMPK
modulator AICAR (25 µM), mTORC1 inhibitor rapamycin (rap, 300 nM),
VPS34 and ULK1 inhibitors SAR405 (1 µM) and MRT68921 (5 µM), AKT1
inhibitor MK-2206 (1 µM), BECN1-stabilizers SMIP004 (S004, 10 µM),
valinomycin (val, 5 µM), niclosamide (nic, 10 µM) or DMSO (vehicle,
dashed lines). For siRNA knockdown, VeroFM cells were transfected with
60 nM siRNA targeting ATG5, ATG7, FIP200, BECN1, and infected with
SARS-CoV-2 48 h later. SARS-CoV-2 infectious virus particle units (PFU)
and genome equivalents (GE) per ml were determined by plaque assay and
real-time RT-PCR at 24 h p.i., respectively. Data are presented as fold
differences (see Supplementary Fig. 11 for unprocessed data). In all panels,
error bars =SEM derived from n= 3 (n= 2 for spd, spm, AICAR)
biologically independent samples from one experiment. Statistics were
done for experiments with n= 3 using a two-way ANOVA, Dunnett’s, and
one-way ANOVA for siRNA knockdown experiments (green). Compounds
with significant SARS-CoV-2 inhibition (spm, spd, MK-2206, S004, val,
nic) in VeroFM cells were confirmed in Calu-3 cells (see Supplementary
Fig. 11f–g). p≤ 0.05 (*), p≤ 0.01 (**), p≤ 0.001 (***), p≤ 0.0001 (****),
p > 0.05 (not significant, ns). Abbreviations: AICAR, 5-Aminoimidazole-4-
carboxamide ribonucleotide; AKT1, RAC-alpha serine/threonine-protein
kinase; AMPK, AMP-activated protein kinase; ATG5, autophagy-related 5;
ATG7, ubiquitin-like modifier-activating enzyme ATG7; ATG12, ubiquitin-
like protein ATG12; aut, autophagosome; BECN1, Beclin-1 protein; CLEAR,
coordinated lysosomal expression and regulation; cmpd, compound; EP300,
histone acetyltransferase p300; elF5AH, eukaryotic translation initiation
factor 5A, hypusinated; FIP200, FAK family kinase-interacting protein of
200 kDa; FKBP51, 51 kDa FK506-binding protein; GE, genome equivalents;
lys, lysosome; mTORC1, mechanistic target of rapamycin complex 1; nic,
niclosamide; PFU, plaque-forming units; phag, phagophore; PHLPP, PH
domain leucine-rich repeat-containing protein phosphatase; rap, rapamycin;
S004, SMIP-004; SKP2, S-phase kinase-associated protein 2; spd,
spermidine; spm, spermine; TFEB, transcription factor EB; ULK1, unc-51-like
kinase 1; val, valinomycin; VPS34, phosphatidylinositol 3-kinase catalytic
subunit type 3.
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Supplementary Fig. 11a) suggesting that autophagy initiation
through inhibition of mTORC1 affects infectious particle produc-
tion more than virus replication. Limited efficiency of rapamycin
might also be connected to saturated amino acid levels (see Fig. 1c).
In contrast, reduction of autophagy initiation and nucleation by
ULK1 and VPS34 inhibitors (5 µM MRT68921 and 1 µM SAR405,
respectively)44,45 promoted SARS-CoV-2 propagation by up to
492% for MRT68921 (132% GE/ml) and 213% (144% GE/ml) for
SAR405. The enhanced infectious particle formation compared to
GE/ml suggests that autophagy inhibition plays an important role
in virus particle production (Fig. 4, middle, Supplementary
Fig. 11a). Interestingly, ULK1 and VPS34 are both involved in
the generation of phagophores from ER-derived omegasomes46
that might compete for lipids, necessary for the generation of
convoluted membranes, DMVs, and virus particles. Knockdown of
autophagy-initiating ATG5, ATG7, and FIP200, which are
responsible for expansion and closure of phagophores, promoted
SARS-CoV-2 GE/ml by 488% (ATG5), 354% (ATG7), and 110%
(FIP200), confirming the importance of limiting autophagy for
successful SARS-CoV-2 propagation (Fig. 4, middle, Supplemen-
tary Fig. 11b). Next, we applied the highly selective autophagy-
inducing AKT1 inhibitor MK-220647 (1 µM), which is currently
being tested in a clinical phase II study against breast cancer48.
AKT1 inhibition results in BECN1 up-regulation and autophagy
induction21,49. MK-2206 reduced SARS-CoV-2 propagation by up
to 92% based on infectious particle formation (46%, GE/ml)
further supporting the importance of BECN1 stabilization for CoV
inhibition (Fig. 4, bottom, Supplementary Fig. 11a). As expected,
knockdown of BECN1 enhanced SARS-CoV-2 replication by 200%
(Fig. 4, bottom, Supplementary Fig. 11b). Direct blocking of the
negative BECN1 regulator SKP2 by previously described inhibitors
SMIP004, valinomycin, and niclosamide21 showed SARS-CoV-2
growth inhibition (PFU/ml) from 91% (40%, GE/ml) for SMIP004
to >99% (95% and >99.9%, GE/ml) in case of valinomycin and
niclosamide (Fig. 4, bottom, Supplementary Fig. 11a). As the highly
effective niclosamide is also a vATPase inhibitor and a proton
ionophore, acting as oxidative phosphorylation uncoupler50 that
might affect virus entry51, egress52, and other stages of the virus life
cycle, we further confirmed that niclosamide induces autophagy.
Adding BafA1 after niclosamide treatment showed an enhancing
effect on the lipidation of LC3B as reflected by comparable LC3B-
II/actin ratios between mock- and SARS-CoV-2-infected cells
(Supplementary Fig. 11d). Furthermore, we found that a 24 h pre-
treatment and complete removal of spermidine, spermine, MK-
2206, and niclosamide post SARS-CoV-2 inoculation still showed
inhibitory effects, predominantly on virus particle production,
suggesting prolonged effects on autophagy-induced virus inhibition
(Supplementary Fig. 11e). As VeroFM cells are type I IFN-deficient
and have limited expression of the entry co-factor TMPRSS229,53,
we further confirmed selected findings in human lung Calu-3
cells (Supplementary Fig. 11f). While post-infection treatment
with spermine (100 μM) showed SARS-CoV-2 inhibition, spermi-
dine (100 μM) had little or no effect at 24 h p.i. on infectious
particle production in Calu-3 cells and a limited inhibitory effect
on the virus genome level. However, polyamine levels are cell-type
specific and are often elevated in cancer cells (see also Fig. 1)54,55.
Next, we therefore depleted polyamines by pretreating Calu-3 and
VeroFM cells with difluoromethylornithine (DFMO) for 96 h pre-
infection (Supplementary Fig. 11g). We confirmed the inhibitory
potential of spermidine and spermine in polyamine-depleted Calu-
3 and VeroFM cells both showing comparable SARS-CoV-2
inhibition between 84% PFU/ml (10 μM) and 99% (100 μM) for
spermidine as well as >97% PFU/ml for both 10 μM and 100 μM
spermine (Supplementary Fig. 11g). In agreement with the
VeroFM data, post-infection treatment with MK-2206 reduced
SARS-CoV-2 in Calu-3 cells by 50% (35% GE/ml). Additionally,
BECN1-stabilizing compounds SMIP004, valinomycin, and niclo-
samide reduced SARS-CoV-2 by 43% (but increased GE/ml by
23%), 98% (97% GE/ml), and 99% (>99% GE/ml) in Calu-3 cells,
respectively (Supplementary Fig. 11f).
Polyamine supplementation and autophagy induction mod-
ulate cellular metabolism and limit SARS-CoV-2 growth in
primary human lung cells and intestinal organoids. To further
investigate aspects of drug-induced SARS-CoV-2 inhibition on
cellular metabolism, we addressed the polyamine pathway and the
AKT1/BECN1 axis by infecting VeroFM and Calu-3 cells with
SARS-CoV-2 under treatment with 100 µM spermine (Supple-
mentary Figs. 1–2, PCA, and Supplementary Fig. 12, heatmaps) or
10 µM niclosamide (Supplementary Figs. 1–2, PCA, and Supple-
mentary Fig. 13, heatmaps) and subsequently performed meta-
bolomics 24 h p.i. (Fig. 5a). VeroFM cells showed an increase of
most metabolites as compared to untreated SARS-CoV-2-infected
VeroFM cells (Fig. 5a, Supplementary Fig. 12) likely by TFEB-
dependent upregulation of autophagy genes and re-establishing
autophagic flux15 and metabolite production. In Calu-3 cells,
spermine treatment had minor effects on cellular metabolism,
which is in agreement with the above-suggested high polyamine
baseline levels and limited antiviral effects of exogenous admin-
istration. In contrast, niclosamide reverted the SARS-CoV-2-
induced increase of metabolites in VeroFM cells (Fig. 5a, Sup-
plementary Fig. 13, upper panels), while maintaining comparably
higher metabolite levels in Calu-3 cells (Supplementary Fig. 13,
lower panels). In both cell lines, niclosamide treatment resulted in
elevated AMP/ATP ratios and reduced levels of TCA cycle-related
metabolites (Supplementary Fig. 13), probably by induction of
mitochondrial fragmentation56, mitophagy57, and stabilization of
SKP2/BECN1-dependent autophagy21.
To confirm that stabilizing polyamine metabolism by exogen-
ous spermine supplementation and inducing autophagy by
niclosamide treatment have antiviral effects in complex cell
systems, we infected and treated primary human airway epithelial
cells (AEC) and intestinal organoids. For both compounds,
SARS-CoV-2 inhibition reached 94-99% PFU/ml and >94%
GE/ml in AEC at 24 and 48 h p.i. (Fig. 5b, Supplementary
Fig. 14a) and 68-86% PFU/ml and 68-94% GE/ml in intestinal
organoids at 48 and 72 h p.i. (Fig. 5c, Supplementary Fig. 14b).
Finally, for clinical applications, half-maximal inhibitory con-
centration (IC50) of compounds should be in a non-toxic range
and reach adequate plasma levels. For the most promising
polyamine metabolism- and autophagy-stabilizing compounds,
the IC50 was 136.7 μM for spermidine, 7.67 μM for spermine,
0.11 μM for MK-2206, and 0.13 μM for niclosamide, based on
virus infectious units (Fig. 5d, Supplementary Fig. 14c). Maximal
inhibition of infectious virus was achieved with non-toxic
concentrations of 333.3 μM for spermidine (85%), 37 μM for
spermine (>99%), 3.7 μM for MK-2206 (88%), and 1.24 μM for
niclosamide (>99%).
Discussion
Our data show that highly pathogenic SARS-CoV-2 reprograms
the metabolism of cells, induces ubiquitination, and limits
autophagy (graphical abstract and working model, Supplemen-
tary Fig. 15a, b). SARS-CoV-2 inhibits autophagy as part of its
manipulation of the host cellular machinery, whereas the
induction of autophagy initiation limits SARS-CoV-2 propaga-
tion. Our mechanistic approach, including metabolomics,
autophagy signaling, and targeted SARS-CoV-2 inhibition assays,
identified two main autophagy-related putative drug targets: the
polyamine pathway, and the control of BECN1 abundance
through AKT1/SKP2 signaling.
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Regarding the polyamine pathway, we found in vitro and in vivo
evidence for transcriptional activation of SAT1, which is respon-
sible for acetylation of spermidine and spermine and their con-
version to putrescine. Indeed, the putrescine levels were increased
in SARS-CoV-2-infected VeroFM and Calu-3 cells suggesting
enhanced SAT1 activity. As an ISG, SAT1 showed an overall
expression pattern comparable to other ISGs in our in vitro and
in vivo data except for ciliated lung cells from mucosal brushes of
COVID-19 patients (Fig. 3d). Patients with low SARS-CoV-2 RNA
levels expressed significantly more SAT1 that would reduce sper-
midine levels and autophagy similar to what we observed in our
in vitro experiments. The expression pattern inverted to increased
ISG levels but reduced SAT1 in patients with high SARS-CoV-2
RNA concentrations. The virus concentration-dependent tran-
scriptional dynamics suggest direct intervention of SARS-CoV-2
into immune and autophagy gene regulations. High SARS-CoV-2
RNA level-dependent SAT1 downregulation might be explained by
a SARS-CoV-2 papain-like protease-driven degradation of P5358,
which is key to SAT1 activation59. Interestingly, it has previously
been shown that spermidine-dependent eIF5A hypusination,
which inversely correlates with aging, is also a key factor in efficient
B cell activation15. Our findings suggest that SAT1 manipulation is
a possible mechanism by which SARS-CoV-2 evades a durable
antibody response, as preliminary reports have indicated60. Addi-
tionally, the proposed SARS-CoV and SARS-CoV-2 NSP2 inter-
actions with mitochondrial-residing proteins such as prohibitin
(PHB)1 and 2, STOML2, and VDAC2 might limit mitophagy61–63
and P53-dependent SAT1 activation64. Damaged mitochondria
might accumulate in the host cell, with consequences for ATP
production and release of reactive oxygen species.
Other explanations for limited autophagy in SARS-CoV-2-
infected cells include recently described ORF3a, ORF7a, NSP15
involvement65, and particularly NSP1-dependent host protein
translational shutoff26,27 that might prevent the synthesis of
autophagy-regulating proteins, maintain a high ATP/AMP ratio,
and increase amino acid availability. The reduction of multiple
Fig. 5 Polyamine supplementation and autophagy induction modulate cellular metabolism and limit SARS-CoV-2 growth in primary human lung cells
and intestinal organoids. a Analysis and regulation of significantly altered pathways of SARS-CoV-2-infected VeroFM cells (24 h p.i.) upon treatment
with spermine (spm, 100 µM, thin outlined circles) or niclosamide (nic, 10 µM, solid outlined circles). Analysis was done as described in Fig. 1 (n= 4 biological
independent replicates per group, one experiment). All p-values were determined by a two-way ANOVA and Tukey´s post hoc test. FDRs were adjusted
using the Benjamini-Hochberg method. b Primary human airway epithelial cells (n= 6, from two independent experiments with n= 3) were infected with SARS-
CoV-2 (MOI=0.1) and treated with spm, nic, or vehicle as mentioned in a for 24 h and 48 h, respectively. P-values were determined by two-way ANOVA,
Dunnett’s, mean with SEM. c Human intestinal organoids (n= 8, from two independent experiments with n= 4) were infected with SARS-CoV-2 (MOI=0.05)
and treated with spm, nic, or vehicle as above for 48 and 72 h, respectively. Data are presented as fold change PFU/ml or GE/ml. Two-way ANOVA, Dunnett’s,
mean with SEM was used for p-value calculation. Technical outliers were removed resulting in n= 7 for spm, 72 h p.i. (PFU/ml), and nic, 48 h p.i. (GE/ml) as
well as n= 6 for veh, 72 h p.i. (GE/ml). d VeroFM cells were infected with SARS-CoV-2 (MOI=0.0005) and treated with increasing concentrations of
spermidine (spd), spm, MK-2206, and nic (n= 3 biological replicates per concentration from one experiment, mean with SEM) to calculate the 50% inhibitory
concentration (IC50). Technical outliers were removed resulting in n= 2 for nic, 0.046 µM, 48 h p.i. (PFU/ml). Limit of detection (LOD) of the plaque assay was
50. Data are presented as percentages of the negative control (see Supplementary Fig. 14 (raw data) and Fig. 10 (cytotoxicity assays)). p≤0.05 (*), p≤0.01
(**), p≤0.001 (***), p≤0.0001 (****), p > 0.05 (not significant, ns). Abbreviations: GE, genome equivalents; LOD, limit of detection; met., metabolism; nic,
niclosamide; PFU, plaque-forming units; spd, spermidine; spm, spermine; veh, vehicle.
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autophagy-regulating proteins, including key regulator BECN1,
led to reduced ATG14 oligomerization and limited fusion of
AP with lysosomes in agreement with previously described
mechanisms22 and similar to MERS-CoV21. Noteworthy, despite
the relatively global reduction of several autophagy-regulating
proteins the most pronounced effect seems to be on the inhibition
of AL fusion resulting in P62 and LC3B accumulation in vitro
and in vivo that might be explained by a recently discovered
ORF3a-mediated mechanism affecting VPS39 and HOPS-RAB7-
interaction66. The recently described SARS-CoV-2-induced
deacidification of lysosomes, necessary for viral egress52,
would further contribute to reduced AL formation, disruption of
autophagic flux, accumulation of P62 and LC3B, and subse-
quently reduced protein degradation. As virus production relies
on available amino acids provided either by anabolic synthesis or
catabolic recycling processes, the observed global K48-dependent
ubiquitination and subsequent proteasomal degradation of cel-
lular proteins might additionally compensate for the limited
autophagy-dependent untargeted protein degradation. As global
K48-ubiquitination modulates cellular pathways including anti-
viral IFN and proinflammatory responses67, deubiquitinating and
deISGylating functions of the CoV nsp3-encoded papain-like
protease68 might balance UPS-linked amino acid supply and
cellular antiviral countermeasures. In summary, SARS-CoV-2
limits autophagy-dependent protein degradation, possibly to
prevent virus particle destruction, drive deacidified lysosome-
dependent virus egress52 and exploit autophagy-related lipid
resources for omegasome-dependent DMV formation and virus
particle production69.
The IC50 values of the tested compounds indicated efficient virus
inhibition in vitro and in ex vivo lung and intestinal models,
encouraging clinical trials. Spermidine/spermine plasma levels in
humans range between 12–29 ng/ml or 70-280 nM70,71 being up to
1,000-fold below the detected IC50. Such a high IC50 might be
expected, as spermidine is an endogenous metabolite with intra-
cellular concentrations of 500 μM or more72. As long-term sper-
midine supplementation increased intracellular levels of polyamines
in polyamine-deprived cells in old-aged individuals73, further well-
designed in vitro and in vivo studies should clarify putative benefits
of polyamine supplementation before or during SARS-CoV-2
infection. Regarding MK-2206, a clinical phase II study found peak
plasma concentrations of 0.176 μg/ml (430 nM)74, which was well
above the IC50 value of 0.11 μM determined here. A phase I clinical
study of niclosamide has reported peak plasma concentrations
ranging from 35.7–182 ng/ml (109–556 nM)75, which encompasses
the IC50 value of 0.13 μM reported here. Niclosamide is known to
have limited resorption efficacy, which might be enhanced by
improving the niclosamide formulation or by developing an
inhalable derivate for local application76. Both MK-2206 and
niclosamide might be promising candidates for clinical trials. This
work paves the way for the identification and rational design of
effective autophagy-modulating antiviral compounds.
Methods
Ethics. The use of primary lung tissue was approved by the Charité ethics com-
mittee (projects EA2/079/13 to Andreas Hocke) and written informed consent was
obtained from all patients. The use of COVID-19 patient samples applied in his-
topathology and sequencing was approved by the Ethics Committee of the Charité
(EA1/144/13, EA2/066/20 and EA1/075/19 to Helena Radbruch) as well as by the
Charité-BIH COVID-19 research board and complied with the Declaration of
Helsinki. The generation and cultivation of human primary intestinal organoid
cultures was done under the ethics approval no. EA4/164/19 (to Markus Morkel).
All animal work was done in compliance with relevant national and international
guidelines for care and humane use of animals. The animal use protocol was
approved by the Landesamt für Gesundheit und Soziales in Berlin, Germany
(approval number 0086/20; approved on 30.04.2020) as described37.
Chemicals. The following chemicals were used for treatment of cells: AICAR
(Sigma–Aldrich, A9978), BafA1 (Alfa Aeser, J61835), rapamycin (RAP, Tocris,
1292), niclosamide (NIC, Sigma–Aldrich, Munich, Germany, N3510), valinomycin
(VAL, Sigma–Aldrich, V0627), MG132 (Sigma–Aldrich, M8699), MK-2206 HCl
(Cayman Chemical, 11593), MRT68921 (Sigma–Aldrich, SML 1644), SMIP004
(Maybridge Chemicals, TL00829SC), DSS (disuccinimidyl suberate, Thermo Fisher
Scientific, 21655), SAR405 (Sigma–Aldrich, 5.33063), Spermine (Sigma–Aldrich,
S4264-5G), Spermidine (Sigma–Aldrich, 85558-5 G), DFMO (Sigma-Aldrich,
D193-25MG).
Cells. VeroFM (ATCC CCL-81), VeroE6 (ATCC CRL-1586), Calu-3 (ATCC HTB-
55) and NCI-H1299 (ATCC CRL-5803) were cultivated in Dulbecco’s Modified
Eagle´s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1%
penicillin/streptomycin, 1% non-essential amino acids, and 1% sodium pyruvate at
37 °C and 5% CO2. To exclude the possibility of FBS-dependent ROS production,
pilot experiments with spd and spm were additionally carried out using human
serum or aminoguanidine instead of FBS.
Virus strains and infection. The applied SARS-CoV-2 strain Munich/2020/984
(BetaCoV/Munich/BavPat1/2020) was isolated from a respiratory swab obtained
from the early 2020 Munich patient cohort (GenBank: MT270101; GISAID:
EPI_ISL_406862). For virus infection with SARS-CoV-2 strain Munich 984, 2 x
10e5 cells ml-1 were seeded in 6-well plates. After 24 h, cells were infected with an
MOI= 0.0005 or 0.1 for infection of primary airway epithelial cells in serum-free
medium. In parallel, mock-infected cells were inoculated with heat-inactivated
(95 °C, 10 min) virus. After 1 h, the virus dilutions were removed, and the wells
were washed twice with PBS and refilled with DMEM (supplemented as described
above). Samples were taken at the indicated time points. All virus infection
experiments were conducted under biosafety level 3 conditions with enhanced
respiratory personal protection equipment. For viral RNA extraction, 50 µl of cell
culture supernatant was mixed with 300 µl MagNA Pure external lysis buffer
(Roche, Penzberg, Germany) followed by 70 °C for 10 min. Extraction was done by
automated pipetting using MagNA Pure 96 instrument (Roche).
Primary airway epithelial cells and intestinal organoids. Lung explants were
obtained from patients suffering from lung carcinoma, who underwent lung
resection at local thoracic surgeries. The study was approved by the Charité ethics
committee (projects EA2/079/13) and written informed consent was obtained from
all patients. Cells were isolated from tumor-free peripheral lung tissue and cultured
as described77. For expansion primary cells were co-cultivated with gamma-
irradiated mitotically inactivated NIH3T3 mouse embryonic fibroblasts (MEFs)
with additional supplementation of 0.1 µM DBZ (Tocris). Differentiation was
induced as described and two days prior to infection primary cells were separated
from MEF cells by differential trypsinization and seeded in cell culture vessels in
DMEM with 10% FCS, 1% non-essential amino acids, 1%, L-glutamine, and 1%
sodium pyruvate. Airway epithelial cells were infected with an MOI= 0.1 as
described above. Human normal colon organoids were established and cultured as
previously published78. Normal colon organoids were established from non-
cancerous parts of colorectal cancer resection tissue (descending colon), and cul-
tured as previously published. Patient-derived organoid lines were established
under ethic´s vote EA4/164/19 of the ethics commission of Charité Uni-
versitätsmedizin Berlin. Organoids were harvested, Matrigel (Corning, #356231)
was removed by centrifugation and subsequently infected in solution with an MOI
= 0.05 as described above. Infected organoids were seeded in Matrigel and medium
was supplemented with compounds or vehicle control.
Real-time reverse-transcription PCR. SARS-CoV-2 GE/ml were detected by real-
time RT-PCR assay targeting SARS-CoV-2 E gene as reported before and listed in
Supplementary Table 1179. Absolute quantification was performed using SARS-
CoV-2-specific in vitro-transcribed RNA standards. Cellular SQSTM RNA
(encoding P62) was quantified by real-time RT-PCR using the Superscript III
OneStep RT-PCR kit and oligonucleotides p62_f, p62_r, p62_p (listed in Supple-
mentary Table 11). Total RNA was isolated from SARS-CoV-2-infected VeroFM or
Calu-3 cells by automated pipetting using the MagNA Pure 96 instrument.
SQSTM1 expression was calculated relative to TBP reference gene expression using
the ΔΔCT method80.
Plaque assay. Infectious SARS-CoV-2 plaque-forming units (PFU) were quanti-
fied by plaque titration on VeroE6 cells81. VeroE6 monolayers were seeded in
24-well plates to reach 90% confluency after 24 h, washed with PBS, incubated with
serial dilutions of SARS-CoV-2-containing cell culture supernatants (duplicates,
each 200 µl in OPTIPro medium), and overlaid with 1.2% Avicel in DMEM. After
72 h, cells were fixated with 6% formalin and visualized by crystal violet staining.
The assay-specific cut-off is 50 PFU/ml.
siRNA knockdown experiments. Knockdown experiments were done using
dsiRNA transfection82. Briefly, 5x10e4 VeroFM cells were seeded in 24-well plates
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and transfected using 60 nM siRNA per well using X-tremeGENE™ (Roche) and a
reagent/RNA ratio of 3:1, following the manufacturer’s instructions. After 48 h the
transfection mix was removed, cells were infected with SARS-CoV-2 at an MOI of
0.0005, and samples were taken at 24 h p.i. The following dsiRNAs were obtained
from Integrated DNA Technologies (IDT, Leuven, Belgium): ATG5 (CD.
Ri.222020.13.1), ATG7 (CD.Ri.222051.13.1), BECN1 (CD.Ri.222059.13.1), FIP200
(CD.Ri.222075.13.3) as well as non-targeting negative control dsiRNAs. Successful
knockdown of the indicated targets was verified by Western blot analysis. Protein
samples were taken 48 h after siRNA transfection and processed as
mentioned below.
Experimental growth conditions for metabolic profiling and isotope tracing
experiments. In the differential experimental conditions VeroFM and Calu-3 cells
were seeded (5×106 cell/ml) in quadruplicates in 6-well MTPs in the presence of
DMEM, DMEM containing 10 µM niclosamide in DMSO, DMEM containing the
corresponding amount of DMSO as compared to the 10 µM niclosamide treatment
or DMEM containing 100 µM spermine. All these conditions were additionally
incubated for 24 h in the presence of SARS-CoV-2 or heat-inactivated SARS-CoV-
2 (mock) at an MOI of 0.1. For isotope tracing experiments, Calu-3 cells were
seeded (5 × 106 cell/ml) in six replicates in 6-well MTPs containing 25 mM U-13C6-
labeled glucose (Sigma Aldrich, 660663). The cells were grown for 4 h in the
presence of MOI of 0.1 of either SARS-CoV-2 or mock control.
Metabolite extraction for Liquid Chromatography mass spectrometry
(LC-MS). At the end of each treatment, the growth media from each well was
aspirated and the adherent cells were washed twice with 1 ml of pre-warmed
(37 °C) wash buffer (75 mM ammonium carbonate (pH 7.4) (VWR NORMAPUR,
21217.260) in Optima LC/MS Grade water, (Thermo Fisher Scientific)). Metabolite
extraction from each well was performed for 20 min in 400 µl of a pre-chilled
mixture of acetonitrile:methanol:water (40:40:20 [v:v:v] (all solvents Optima LC/
MS grade, Thermo Fisher Scientific)) at −20 °C. After removing the extraction
solvent and storing it on ice, the extraction was repeated a second time but now the
cells were scraped from the plate surface and pooled with the first extract. The
combined were subsequently heated to 70 °C for 10 min, to inactivate the virus,
before centrifuging them for 10 min at 21,100 g. The metabolite-containing
supernatant was transferred to a fresh tube and dried immediately in a Speed Vac
concentrator (Eppendorf) before storing it until analysis at −80 °C.
LC-MS analysis of amine-containing metabolites. For the analysis of amine-
containing compounds, a benzoyl chloride derivatization method83 was used.
Briefly, the dried metabolite pellets were re-suspended in 1500 µl of water (Optima
LC/MS grade, Thermo Fisher Scientific). 50 µl of the re-suspended sample was
mixed with 25 µl of 100 mM sodium carbonate (Sigma-Aldrich, S7795) in Optima
grade LC-MS water (Thermo Fisher Scientific) followed by the addition of 25 µl 2%
[v:v] benzoyl chloride (Sigma-Aldrich, B12695) in acetonitrile (Optima LC/MS
Grade, Thermo Fisher-Scientific). Samples were vortexed briefly and centrifuged
for 10 min at 21,300 g at 20 °C. Clear supernatants were transferred to fresh auto-
sampler tubes with conical glass inserts (Chromatographie Zubehoer Trott) and
analyzed using an Acquity i-class UPLC (Waters) connected to an Orbitrap ID-X
tribrid mass spectrometer (Thermo).
For the analysis 1 µl of the derivatized sample was injected onto a 100 ×2.1 mm
HSS T3 UPLC column (Waters). The flow rate was set to 400 µL/min using a buffer
system consisting of buffer A (10 mM ammonium formate (Sigma–Aldrich,
70221), 0.15% formic acid (Sigma-Aldrich, 33015) in Optima LC/ MS-grade water,
Thermo Fisher Scientific), and buffer B (acetonitrile, Optima LC/MS grade,
Thermo Fisher Scientific). The LC gradient was: 0% B at 0 min; 0–15% B
0–0.1 min; 15–17% B 0.1–0.5 min; 17–55% B 0.5–7 min, 55–70% B 7–7.5 min;
70–100% B 7.5–9 min; 100% B 9–10 min; 100-0% B 10–10.1 min, 10.1–15 min 0%
B. The mass spectrometer (Orbitrap ID-X, Thermo Fisher Scientific) was operating
in positive ionization mode monitoring the mass range m/z 50–750. The heated
ESI source settings of the mass spectrometer were: Spray voltage 3.5 kV, capillary
temperature 300 °C, sheath gas flow 60 AU, and aux gas flow 20 AU at a
temperature of 250 °C. Data analysis was performed using the TraceFinder
software (Version 4.1, Thermo Fisher Scientific). Identity of each compound was
validated by authentic reference compounds, which were analyzed independently.
Peak areas were analyzed by using extracted ion chromatograms (XIC) of
compound-specific [M+ nBz + H]+ where n corresponds to the number of amine
moieties that can be derivatized with benzoyl chloride (Bz). XIC peaks were
extracted with a mass accuracy (<5 ppm) and a retention time (RT) tolerance of
0.05 min.
Anion-Exchange Chromatography-Mass Spectrometry (AEX-MS) of the
analysis of TCA cycle and glycolysis metabolites. Anion-Exchange Chroma-
tography was performed in parallel to the LC-MS analysis of amines. For this
purpose, 100 µl of the initially re-suspended sample were analyzed using a Dionex
ion chromatography system (Integrion, Thermo Scientific). The applied protocol
was adopted from84. Briefly, 5 µl of the aqueous metabolite extract were injected in
full loop mode using an overfill factor of 3, onto a Dionex IonPac AS11-HC
column (2 mm × 250 mm, 4 μm particle size, Thermo Scientific) equipped with a
Dionex IonPac AG11-HC guard column (2 mm × 50mm, 4 μm, Thermo Scien-
tific). The column temperature was held at 30 °C, while the auto-sampler was set to
6 °C. A potassium hydroxide gradient was generated by the eluent generator using
a potassium hydroxide cartridge that was supplied with deionized water. The
metabolite separation was carried at a flow rate of 380 µl/min, applying the fol-
lowing gradient. 0–3 min, 10 mM KOH; 3-12 min, 10−50 mM KOH; 21–19 min,
50–100 mM KOH, 19–21 min, 100 mM KOH, 21–22 min, 100–10 mM KOH. The
column was re-equilibrated at 10 mM for 8 min. The eluting metabolites were
detected in negative ion mode using a Q-Exactive HF mass spectrometer (Thermo
Fisher Scientific). The mass spectrometer was operating in negative ionization
mode monitoring the mass range m/z 50-750. The heated ESI source settings of the
mass spectrometer were: Spray voltage -3.0 kV, capillary temperature 300 °C,
sheath gas flow 60 AU, and aux gas flow 20 AU at a temperature of 300 °C.
Data analysis was performed using the TraceFinder software (Version 4.1).
Identity of each compound was validated by authentic reference compounds, which
were analyzed independently. Peak areas were analyzed by using extracted ion
chromatograms (XIC) of compound-specific [M – H+]-. XIC peaks were extracted
with a mass accuracy (<5 ppm) and a retention time (RT) tolerance of 0.1 min.
13C Isotope enrichment analysis after U-13C6 Glucose tracing. 13C isotope
enrichments for all detectable isotopologues were performed using the TraceFinder
(Version 4.1). Identity of each compound was validated by reference compounds
using either the [M–H+]- ion from anion chromatographic data or the [M+
nBz+H+]+ ion from the data obtained from the benzoyl-derivatized amines
analysis.
For the differential isotope enrichment analysis the sum of all peak areas of the
extracted isotopes of a compound was calculated and the fraction of the individual
isotope to the sum of isotopes was calculated (isotope enrichment analysis). Based
on the relative enrichment of each isotopologue the fraction of the labeled isotopes
of each compound was determined. This atom fraction labeled represent the
relative contribution of stable 13C isotopes to the total area of each compound
(denoted as atom fraction labeled in Supplementary Fig. 4a-b). Isotopologue peaks
were extracted using a mass accuracy (<5 ppm) and a retention time tolerance of
<0.05 min.
Analysis of metabolomics data. Identification of significant metabolite level
alterations: Metabolite intensities were log2 transformed and Pareto-scaled for
further statistical analysis. Significant metabolite level changes upon 24 h p.i.
compared to mock were identified by Student’s T-test with an adjusted p-value
(false discovery rate (FDR)) ≤ 0.05 using MetaboAnalyst85. Identification of sig-
nificantly overrepresented pathways: Metabolomics pathway analyses were per-
formed with the significantly altered metabolites from Supplementary Tables 1 and
2 using MetaboAnalyst applying a Fisher’s Exact Test and Out-degree Centrality
for pathway topology analysis. Pathways were considered for further analyses with
an FDR ≤ 0.185. Heat map data (Supplementary Figs. 12 and 13) was generated
from log10 transformed and z-score scaled data using the InstantClue v.0.10.10.
dev-snap software86.
Toxicity assays. Presto Blue cell viability and LDH cytotoxicity assays in VeroFM
or Calu-3 cells were carried out according to the manufacturer’s protocols provided
by ThermoFisher Scientific and Takarabio, respectively. Briefly, for PrestoBlue cell
viability assay, cells were incubated in the presence of 10 µl PrestoBlue (10x)
reagent for 30 min at 37 °C and 5% CO2 after the indicated treatment times.
570 nm absorbance values were normalized to 600 nm values for further analysis.
For LDH cytotoxicity assays, 100 µl of cell-free supernatant was measured for LDH
activity at 492 nm after the indicated treatment times. A wavelength >600 nm
served as reference wavelength. For MTT tests, cells were incubated in the presence
of 0.5 mg ml−1 tetrazole 3-(4,5-dimethylthiazol-2-yl-)-2,5-diphenyltetrazolium
bromide (MTT) for 4 h at 37 °C and 5% CO2. Read-out of MTT assay was carried
out as described in the manual instructions21.
Protein analysis, Western blot and Atg14 oligomerization. Protein extracts
were obtained by lysing cells in Pierce IP Lysis buffer freshly supplemented with
protease inhibitor cocktail 3 (Merck Millipore, Darmstadt, Germany), and phos-
phatase inhibitor PhosSTOP (Roche, Penzberg, Germany). Subsequently, SDS
loading buffer (4x NuPAGE LDS, ThermoFisher Scientific) was added and samples
were heated to 95 °C for 10 min to inactivate SARS-CoV-2. Proteins were separated
by SDS-PAGE and electro-transferred onto PVDF membranes21. Blots were placed
in Tris-buffered saline, supplemented with 0.05% Tween (Sigma Aldrich) and 5%
non-fat milk for 1 h at room temperature, and then incubated with primary
antibody (diluted in TBS/0.05% Tween) overnight at 4 °C. Subsequently, blots were
washed and probed with the respective horseradish peroxidase- or fluorophore-
conjugated secondary antibody for 1 h at room temperature. The immuno-reactive
bands were visualized either using ECL detection reagent (Millipore, Billerica, MA,
USA) or directly by excitation of the respective fluorophore. Determinations of the
band intensities were performed with BioRad, ChemiDoc MP.
The following primary antibodies were used: β-actin (1:5,000 Cell Signaling
Technology, #8457), SQSTM1/p62 (1:1,000, Cell Signaling Technology, #5114),
LC3B (1:1,000, Cell Signaling Technology, #3868), BECN1 (1:1,000, Cell Signaling
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Technology, #3738), pBECN1S15 (1:1,000, Cell Signaling Technology, #84966),
ATG14 (1:1,000, Cell Signaling Technology, #5504), pATG14S29 (1:1,000, Cell
Signaling Technology, #13155), ULK1 (1:1,000, Cell Signaling Technology, #8054),
pULK1 (S555) (1:1,000, Cell Signaling Technology, #5869), pULK1 (S757) (1:1,000,
Cell Signaling Technology, #6888), TSC2 (1:1,000, Cell Signaling Technology,
#3612), pTSC2 (S1387) (1:1,000, Cell Signaling Technology, #5584), AMPKα
(1:1,000, Cell Signaling Technology, #2532), pAMPK (T172) (1:1,000, Cell
Signaling Technology, #2531), pAMPK substrate motif (1:1,000, Cell Signaling
Technology, #5759), pAKT (S473) (1:1,000, Cell Signaling Technology, #4060),
AKT (1:1,000, Cell Signaling Technology, #9272), HSC70 (1:5,000, Enzo Life
Sciences, ADI-SPA-757-F), SKP2 (1:1,000, Cell Signaling Technology, #2652),
pSKP2 (S64) (1:1,000, Cell Signaling Technology, #14865). Anti-pSKP2 (S72) was a
kind gift by Cell Signaling Technology (used 1:1,000). Secondary antibodies: anti-
rabbit IgG, HRP-linked antibody (1:10,000, Cell Signaling Technology, #7074),
anti-mouse IgG, HRP-linked antibody (1:10,000, Cell Signaling Technology,
#7076). The immunoreactive bands were visualized using ECL detection reagent
(BioRad, Hercules, CA, USA). Determination of the band intensities was
performed with BioRad, ChemiDoc MP. In general, protein quantification was
performed by normalization to the intensity of actin or HSC70, which was
determined on the same membrane. For quantification of phosphorylated proteins,
this signal was always referred to the signal intensity of the corresponding total
protein. For ATG14 oligomerization, the PBS-washed cell pellet was incubated with
75 µM DSS (disuccinimidyl suberate, Thermo Fisher Scientific, 21655) or
corresponding vehicle (DMSO) in PBS. Crosslinking was performed for 30 min at
room temperature followed by 2 h, at 4 °C. Crosslinking was quenched in Tris-
buffered saline (pH 7.0) for 20 min at 4 °C. Protein extracts were analyzed by
capillary electrophoresis on Wes™ (ProteinSimple) using the 60–440 kDa cartridges.
Autophagic flux, GFP-FYVE, and immunofluorescence test. To determine the
effect of drug treatment or CoV infection on autophagic flux, DMSO (vehicle
control) or BafA1 were applied two hours before cell lysis, followed by Western
blot analysis as described. In order to detect autophagosomes and autophagoly-
sosomes by immunofluorescence test, VeroFM and NCI-H1299 cells were trans-
fected with ptfLC3 plasmid (Addgene.org, #21074) that expresses LC3 tagged with
both GFP (inactivated in autolysosomes) and mRFP (resists inactivation in
autolysosomes)36, following the guidelines for monitoring autophagy32. For
transfections, cells were treated with 0.5 µg plasmid and 1.5 µl Fugene HD (Pro-
mega, Mannheim, Germany) 24 h prior to infection with SARS-CoV-2 (MOI=
0.001) and drug treatment the next day. Cells were fixed (6% formaldehyde for 1 h)
at indicated time points (24 h) and analyzed by fluorescence microscopy (AxioVert
200M, Carl Zeiss, Oberkochen, Germany) equipped with a plan-Apochromat 63x/
1.40 Oil DIC objective and an AxioCam MR R3 camera. Images were acquired and
processed using AxioVision software ZEN Pro 2 (Carl Zeiss). A scientist blind to
the conditions counted vesicles in 40-50 randomly selected cells. For GFP-FYVE
detection VeroFM cells were transfected with GFP-FYVE and infected with SARS-
CoV-2. After 24 h p.i. cells were fixed and stained with an undiluted hybridoma
culture supernatant of an in-house mouse monoclonal anti-SARS-CoV-2 nucleo-
capsid antibody (#G229FA10; kindly provided by J. A. Schenk and F. Sellrie; UP
Transfer GmbH, Potsdam). Secondary antibody detection was done with Cy3-
labeled polyclonal goat-anti mouse antibody (1:200, Dianova, 115-165-166).
Autopsy lung tissue. This study was approved by the Ethics Committee of the
Charité (EA 1/144/13, EA2/066/20 and EA1/075/19) as well as by the Charité-BIH
COVID-19 research board and complied with the Declaration of Helsinki. For
histology, we analyzed cryopreserved lung tissue from deceased patients that were
tested positive for SARS-CoV-2 RNA via PCR79. Lung tissue from deceased
patients with clinical and autoptic signs of non-COVID pneumonia (n= 3) and
without signs of pneumonia (n= 3) was used as controls. COVID-19 patients were
randomly selected out of our autopsy cohort (n= 6 out of 25)87. Inclusion criteria
were presence of cryopreserved material and viral RNA load in the lungs. Patients
were excluded if tumor infiltration could be detected in the samples and one case
with graft vs host reaction after stem cell therapy. For single-nucleus (sNuc) RNA
sequencing cases were selected using the same inclusion and exclusion criteria, but
not randomly selected. Instead, cases were selected with respect to the expected
RNA quality and disease duration (early= <14 days, and late= >14 days disease
duration, in total n= 7 out of 25). Clinical records were assessed for pre-existing
medical conditions and medications, current medical course, and ante-mortem
diagnostic findings as specified in Supplementary Table 7. All specimens were
cryopreserved after removal at −80 °C prior to diagnostic work-up.
Morphological Analysis & semi-quantitative assessment of autopsy lung
tissue. All stains were performed on 8μm cryomicrotome sections, with a NX80
cryotome (ThermoFisher, Waltham, Massachusetts, USA) according to standard
procedures. Stains included Hematoxylin and eosin (H&E), LC3 (2G6, nanoTools,
1:50) and p62 (SQSTM1, abcam, 1:100). Immunohistochemical stainings were
performed on a Benchmark XT autostainer (Ventana Medical Systems, Tuscon,
AZ, USA). For each specimen, four random fields of vision were analyzed and
photographed at 40x magnification with an Olympus BX50 microscope, the digital
camera DP25, and cell D software. Positively stained cells were defined by presence
of a nucleus and cytoplasmic staining, counted independently by T.A. and H.R.,
and summed together for the four fields of vision.
Single-cell (Sc)/single-nucleus (sNuc) RNA sequencing. ScRNA-seq from
olfactory mucosal swabs. Previously published scRNA-seq data of olfactory
mucosal swabs from uninfected and infected (moderate and critical cases) SARS-
CoV-2 patients were re-analyzed to assess autophagic factors and their gene
expression levels in vivo38. After selecting for patient samples that were obtained
before 14 days since the onset of symptoms, we analyzed a total of 27,876 cells split
between SARS-CoV-2 with low viral load (“low”, n= 5, <10e5 SARS-CoV-2 RNA
copies per ml), and SARS-CoV-2 with high viral load (“high”, n= 3, >10e5 SARS-
CoV-2 RNA copies per ml). Detailed patient information can be found in Sup-
plementary Table 8.
SNuc-seq from postmortem lungs. For sNuc-seq, fresh frozen lung samples were
used from deceased COVID-19 patients with an early time point of death (“early”,
n= 3) and a late time point of death (“late”, n= 4). The patients were stratified
according to the duration of the disease with early= <14 days, and late= >14 days.
Nuclei were isolated and prepared for sNuc-seq RNA sequencing as previously
described88. Briefly, 50-60 μm lung tissue sections were homogenized using the
loose and tight pestles of glass tissue douncers in citric acid buffer (250 mM
sucrose, 25 mM citric acid, 1 μg/mL Hoechst 33342). The homogenate was suc-
cessively passed through a 100 μm and a 35 μm cell strainer to remove large debris.
This was then centrifuged for 5 min at 500 g at 4 °C. The nuclei were then washed
in 1 ml of citric acid buffer. To remove high amounts of debris, the nuclei were
passed through a density centrifugation gradient by adding an equal volume of S88
citric acid buffer (882 mM sucrose, 25 mM citric acid) to the bottom of the tube
before being centrifuged for 10 min at 1,000 g at 4 °C. The supernatant was care-
fully removed, and the nuclei were resuspended in cold resuspension buffer
(25 mM KCl, 3 mM MgCl2, 50 mM Tris-buffer, 0.4 U/μL RNaseIn Takara 2313 A,
1 mM DTT, 0.4 U/μl SuperaseIn Thermo Fisher Scientific AM2694, 1 μg/mL
Hoechst 33342). The nuclei were counted and then immediately loaded into the
10x Chromium Controller using the 10x Genomics Single Cell 3’ Library Kit v3.1
(10x Genomics; PN 1000223; PN 1000157; PN 1000213; PN 1000122) and the
subsequent reverse transcription, cDNA amplification, and library preparation
were performed according to the manufacturer’s instructions with minor mod-
ifications. Specifically, the 85 °C incubation step during the reverse transcription
step was extended to 10 min and an additional 2 cycles were added to the cDNA
amplification. Afterwards, the 3’RNA sequencing libraries were pooled and
sequenced on the NovaSeq 6000 Sequencing System (Illumina, paired-end, single-
indexing). Single-nucleus postmortem lung dataset was processed using cell ranger
3.0.1. All transcripts were aligned to a customized hg19 reference transcriptome
(10x Genomics, version 3.1.0) that included the SARS-CoV-2 genome (Refseq-ID:
NC_045512) as an additional chromosome. Further pre-processing was performed
with Seurat 3.1.489,90 where cells with more than or equal to 10% mitochondrial
reads or less than 200 genes expressed were filtered out. An upper cutoff for the
number of genes was selected manually for each sample based on the outliers in a
UMI counts vs. gene counts plot (3,000-6,000 genes). After log-normalization,
samples were integrated with canonical correlation analysis (CCA) in Seurat. Using
the integrated dataset, PCA was run, followed by UMAP calculation and finally
clustering. Cell type assignment was performed as previously described38,91 and by
using marker genes92. The postmortem lung dataset is depicted in a UMAP with
the identified cell types identified in uninfected and infected patients with SARS-
CoV-2 (Supplementary Fig. 9a–i). “SARS2high” cells exhibit the expression of AT1,
AT2, and secretory cell markers, which may indicate that this cluster of cells is
composed of different cell types sharing a similar transcriptome due to infection
(Supplementary Fig. 9d). Of note, due to the nature of the sNuc-seq technique,
cytoplasmic transcripts are lost which consequently includes viral RNA transcripts.
It is possible that some SARS-CoV-2+ cells were co-captured with ambient viral
RNA. SARS-CoV-2-positive cells are defined as any cell with >1 viral RNA tran-
script. Some identified cell types are present in different states of maturation as
indicated by differing levels of marker gene expression (Supplementary Fig. 9h).
The differences in the QC metrics of the patient samples might be explained by the
time point of sampling after death (Supplementary Table 7). After pre-processing
and filtering, we analyzed 51,138 nuclei.
Statistics and Reproducibility. When two groups were compared, the Student’s t-
test was applied. For three or more group comparisons, one or two-way analysis of
variance (ANOVA) was performed, as appropriate, followed by Tukey’s or Bon-
ferroni’s or Sidak and Dunnett´s post hoc tests, as appropriate. All t test and
p-values and ANOVA F and p-values are reported in the legends to the Figures and
Supplementary Figures; significant results of the contrast tests are further indicated
by asterisks in the graphs. All statistical tests were two-tailed and p < 0.05 was
considered statistically significant. The asterisks indicate p ≤ 0.05 (*), p ≤ 0.01 (**),
p ≤ 0.001 (***), p ≤ 0.0001 (****), p > 0.05 (not significant, ns). For the complete
set of raw data, see the data source file. For PCA analysis log10 transformed and
pareto scaled and mean-centered peak areas of all samples were analyzed using
SIMCA 13 (Umetrics). Differential gene expression testing was calculated using
FindMarkers with the MAST-based differential expression test. The disease
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duration (postmortem lung) and days post onset of symptoms (olfactory mucosa)
were considered as latent variables. P-values were adjusted using the Benjamini-
Hochberg method. In all cases when virus plaques were not detectable, we inde-
pendently calculated the p-values by considering either the limit of detection of 50
or 0 PFU/ml. Only when both calculations had a p < 0.05 we included a p-value. In
case of the IC50 calculations (Fig. 5d), the end-point was defined as the highest
compound concentration that showed no plaques in all n= 3 samples.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Metabolomics data shown in Figs. 1 and 5, Supplementary Figs. 1–4, 12–13, and
Supplementary Tables 1–4 are available at the Metabolomics data repository
MetaboLights under the study identifier MTBLS2840. Histopathological lung datasets
generated and analyzed during the current study (Fig. 3b) are available on reasonable
request. The sequencing data of Fig. 3c, and Supplementary Fig. 9 are available under
controlled access and require a Data Transfer Agreement in the European Genome-
pheome Archive repository: EGAS00001004689. RNAseq data mentioned in
Supplementary Figs. 5 and 8 are deposited: GSE148729, GSE147507, and
GSE162208. Source data are provided with this paper.
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